Kalaris Therapeutics Inc. – Material Contracts Watch

from 8-K 17 pages Registration Rights Agreement

from 8-K 49 pages Securities Purchase Agreement

from 8-K 15 pages Employment Agreement

from 10-Q 4 pages Kalaris Therapeutics, Inc. Non-Employee Director Compensation Policy

from 10-Q 28 pages Kalaris Therapeutics, Inc. 2020 Stock Option and Grant Plan, as Amended

from 10-Q 61 pages Purpose. the Purpose of This Plan Is to Provide Incentives to Attract, Retain and Motivate Eligible Persons Whose Present and Potential Contributions Are Important to the Success of the Company, Its Parent and Subsidiaries by Offering Eligible Persons an Opportunity to Participate in the Company’s Future Performance Through the Grant of Awards Covering Shares. Capitalized Terms Not Defined in the Text Are Defined in Section 14 Hereof. Although This Plan Is Intended to Be a Written Compensatory Benefit Plan Within the Meaning of Rule 701, Grants May Be Made Pursuant to This Plan That Do Not Qualify for Exemption Under Rule 701 or Section 25102(o). Any Requirement of This Plan That Is Required in Law Only Because of Section 25102(o) Need Not Apply if the Committee So Provides. 2. Shares Subject to the Plan. 2.1

from 10-Q 13 pages Material contract

from 10-Q 16 pages Employment Agreement

from 8-K 8 pages As We Have Discussed, This Letter (The “Offer Letter Amendment”) Shall Amend and Supplement the Terms of Your December 17, 2024 Offer Letter (The “Offer Letter”), Which Sets Forth the Terms and Conditions of Your Employment With Kalaris Therapeutics, Inc. (F/K/a Allovir, Inc., the “Company”). Except as Explicitly Set Forth Herein, the Terms and Conditions of the Offer Letter Shall Otherwise Continue in Full Force and Effect. Specifically, the Following Terms Shall Be Incorporated Into and Supplement the Terms of the Offer Letter: 1. Payments Upon Termination

from 8-K 15 pages Employment Agreement

from 8-K 73 pages Lease Between the Connell Company Landlord and Kalaris Therapeutics, Inc. Tenant 400 Connell Drive

from 8-K 10 pages Kalaris Therapeutics, Inc. [Form Of] Officer Indemnification Agreement

from 8-K 11 pages Kalaris Therapeutics, Inc. [Form Of] Director Indemnification Agreement

from 8-K 42 pages Kalaris Therapeutics, Inc. 2020 Stock Option and Grant Plan, as Amended

from 8-K 53 pages Napoco, Inc. 2019 Equity Incentive Plan as Adopted on September 30, 2019

from 8-K 11 pages December 31, 2024 Matthew Feinsod, MD [***] [***] [***] [***] Re: Offer of Employment by Kalaris Therapeutics, Inc. Dear Matt: I Am Very Pleased to Confirm Our Offer to You of Employment With Kalaris Therapeutics, Inc. (The “Company”). the Terms of Our Offer and the Benefits Currently Provided by the Company Are as Follows

from S-4/A 10 pages April 18, 2024 (As Revised at Your Request on April 26, 2024) Jeffrey Nau, Phd, Mms [***] Re: Offer of Employment by Theia Therapeutics, Inc. Dear Jeff: I Am Very Pleased to Confirm Our Offer to You of Employment With Theia Therapeutics, Inc. (The “Company”). the Terms of Our Offer and the Benefits Currently Provided by the Company Are as Follows

from S-4/A 9 pages February 23, 2024 Andrew Oxtoby [***] Re: Offer of Employment by Theia Therapeutics, Inc. Dear Andrew: I Am Very Pleased to Confirm Our Offer to You of Employment With Theia Therapeutics, Inc. (The “Company”). the Terms of Our Offer and the Benefits Currently Provided by the Company Are as Follows

from 8-K 6 pages Separation Agreement and Release

from S-4 10 pages Consulting Agreement